Federal Register of Legislation - Australian Government

Primary content

PB 59 of 2011 Determinations/Health as made
This Determination amends the National Health Act 1953 - Determination under paragraph 98C(1)(b) - conditions (No. PB 119 of 2008) to provide for changes to the conditions subject to which payments will be made by the Commonwealth in respect of the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners.
Administered by: Health
Registered 29 Aug 2011
Tabling HistoryDate
Tabled HR12-Sep-2011
Tabled Senate12-Sep-2011
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

COMMONWEALTH OF AUSTRALIA

Instrument number PB 59 of 2011

Amendment determination under paragraph 98C(1)(b) of the National Health Act 19531

 

I, FELICITY McNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under paragraph 98C(1)(b) of the National Health Act 1953.

 

Dated 26 August 2011

 

 

 

 

 

 

FELICITY McNEILL

Acting First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

Amendment determination — conditions

1              Commencement                                                        

                This instrument commences on 1 September 2011.

2              Amendment of the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008)

                Schedule 1 amends the Determination under paragraph 98C(1)(b) of the National Health Act 1953 (PB 119 of 2008).



Schedule 1            Amendments

 

[1]        Section 3, in the definition “prescription”

omit:

Chief Executive Officer of Medicare Australia

substitute:

Chief Executive Medicare

 

[2]        Section 9

omit:

Chief Executive Officer of Medicare Australia

substitute:

Chief Executive Medicare

 

[3]        Schedule 1, after entry for Flucloxacillin with Water Purified BP in the form Powder for oral liquid 250 mg (as sodium) per 5 mL, 100 mL

insert:

 

Fluconazole with Water – Purified BP

Powder for oral suspension 50 mg in 5 mL, 35 mL

 

[4]        Schedule 3, after entry for Fentanyl in the form Lozenges 1600 micrograms (as citrate), 30

insert in the column headed “Form (strength, type, size, etc.)”:

 

 

Transdermal patch 1.28 mg

Transdermal patch 2.063 mg

 

[5]        Schedule 3, after entry for Fentanyl in the form Transdermal patch 2.55 mg

insert in the column headed “Form (strength, type, size, etc.)”:

 

 

Transdermal patch 4.125 mg

 

[6]        Schedule 3, after entry for Fentanyl in the form Transdermal patch 7.65 mg

insert in the column headed “Form (strength, type, size, etc.)”:

 

 

Transdermal patch 8.25 mg

 

[7]        Schedule 3, after entry for Fentanyl in the form Transdermal patch 10.20 mg

insert in the column headed “Form (strength, type, size, etc.)”:

 

 

Transdermal patch 12.375 mg

 

[8]        Schedule 3, after entry for Fentanyl in the form Transdermal patch 12.6 mg

insert in the column headed “Form (strength, type, size, etc.)”:

 

Transdermal patch 16.5 mg

[9]        Schedule 4, entry for Calcipotriol with betamethasone

insert as first item in the column headed “Form (strength, type, size, etc.)”:

 

 

Gel containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.